Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Common Equity (2016 - 2025)

Arcadia Biosciences filings provide 12 years of Common Equity readings, the most recent being $4.1 million for Q4 2025.

  • On a quarterly basis, Common Equity fell 33.47% to $4.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.1 million, a 33.47% decrease, with the full-year FY2025 number at $4.1 million, down 33.47% from a year prior.
  • Common Equity hit $4.1 million in Q4 2025 for Arcadia Biosciences, down from $5.4 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $45.7 million in Q1 2021 to a low of $4.1 million in Q4 2025.
  • Median Common Equity over the past 5 years was $16.0 million (2023), compared with a mean of $19.3 million.
  • Biggest five-year swings in Common Equity: soared 273.91% in 2021 and later plummeted 60.81% in 2025.
  • Arcadia Biosciences' Common Equity stood at $31.2 million in 2021, then tumbled by 33.0% to $20.9 million in 2022, then crashed by 39.22% to $12.7 million in 2023, then crashed by 51.01% to $6.2 million in 2024, then plummeted by 33.47% to $4.1 million in 2025.
  • The last three reported values for Common Equity were $4.1 million (Q4 2025), $5.4 million (Q3 2025), and $4.5 million (Q2 2025) per Business Quant data.